Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3566.68% is 96% above its 5-year average of -101283.28%, around the middle of its 5-year range (-360145.45%–202856.82%).
1838.91% below its 12-month average of -183.95%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -919.76%.
NET PROFIT MARGIN
-3566.68%
NET PROFIT MARGIN AVG TTM
-183.95%
NET PROFIT MARGIN AVG 3Y
-102.20%
NET PROFIT MARGIN AVG 5Y
-101283.28%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1838.91%
CURRENT VS 3Y AVG
-3390.04%
CURRENT VS 5Y AVG
+96.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 527 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$516.01M
Net Profit Margin
-3566.68%
TTM Avg
-183.95%
3Y Avg
-102.20%
5Y Avg
-101283.28%
Market Cap
$521.60M
Net Profit Margin
-296000.00%
TTM Avg
-345077.99%
3Y Avg
-146585.06%
5Y Avg
-98190.17%
Market Cap
$542.67M
Net Profit Margin
-1371.51%
TTM Avg
-709.80%
3Y Avg
-108166.39%
5Y Avg
-73106.10%
Market Cap
$491.93M
Net Profit Margin
-6.77%
TTM Avg
-13.38%
3Y Avg
-17.48%
5Y Avg
-11.79%
Market Cap
$487.55M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$538.28M
Net Profit Margin
-56.68%
TTM Avg
-93.15%
3Y Avg
-82.60%
5Y Avg
-71.77%
Market Cap
$540.75M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$479.63M
Net Profit Margin
-3.06%
TTM Avg
-9.59%
3Y Avg
-17.39%
5Y Avg
-29.37%
Market Cap
$479.42M
Net Profit Margin
-10.85%
TTM Avg
-18.16%
3Y Avg
-29.23%
5Y Avg
-75.36%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $516.01M | -3566.68% | -183.95% | -102.20% | -101283.28% |
| Altimmune, Inc. (ALT)vs › | $521.60M | -296000.00% | -345077.99% | -146585.06% | -98190.17% |
| Crescent Biopharma, Inc. (CBIO)vs › | $542.67M | -1371.51% | -709.80% | -108166.39% | -73106.10% |
| NeoGenomics, Inc. (NEO)vs › | $491.93M | -6.77% | -13.38% | -17.48% | -11.79% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| 908 Devices Inc. (MASS)vs › | $538.28M | -56.68% | -93.15% | -82.60% | -71.77% |
| Immix Biopharma, Inc. (IMMX)vs › | $540.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cerus Corporation (CERS)vs › | $479.63M | -3.06% | -9.59% | -17.39% | -29.37% |
| Evolus, Inc. (EOLS)vs › | $479.42M | -10.85% | -18.16% | -29.23% | -75.36% |
| Delcath Systems, Inc. (DCTH)vs › | $548.89M | 0.56% | -33.88% | -929.83% | -984.73% |
Operating Margin
0.0%
Net Profit Margin
-3566.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -919.76% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -295454.55% |
| 2023-12-31 | 202856.82% |
| 2023-09-30 | -283122.73% |
| 2023-06-30 | -360145.45% |
| 2023-03-31 | -333226.67% |
| 2022-12-31 | -201802.13% |
| 2022-09-30 | -169689.80% |
| 2022-06-30 | -86961.63% |
| 2022-03-31 | -130901.64% |
| 2021-12-31 | -146800.00% |
| 2021-09-30 | -159563.27% |
| 2021-06-30 | -161218.18% |
| 2021-03-31 | -86.10% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
